Table 2.

Treatment Characteristics, Primary and Secondary Outcomes

First author (year)	Treatment arm	Patients with active perianal disease	Patients with complete healing of fistulizing disease	Patients at least partial healing of fistulizing disease	Dose escalation regimen	Patients requiring dose escalation	Additional therapy (antibiotics or surgery)
Pestour (2018) [17]	Standard dose VDZ induction and maintenancea	29	5 (17)	NR (assumed to be same 5 patients with complete healing)	If no clinical response at week 6, additional infusion of 300 mg VDZ at week 10, and then once every 4 weeks	NR	NR
Feagan (2018) [16]	Standard dose VDZ induction, maintenance with dosing either every 4 weeks or every 8 weeks, both groups combineda	39	12 (31)	NR (assumed to be same 12 patients with	None	None	Medical treatment (antibiotics) for 21/39
	VDZ induction, followed by placebo maintenance	18	2 (11)	NR (assumed to be same 2 patients with complete healing)
Chapuis-Biron (2019) [11]	Standard dose VDZ induction and maintenancea	102	23 (23)	39 (38)	Patients requiring escalation had 300 mg intravenously every 4 or 6 weeks or 600 mg every 8 weeks	62	Medical treatment (antibiotics) for 39/102 (38%) patients and surgical treatment for 41/102 (40%) patients
Schwartz (2020) [12]	VDZ 300 mg IV at weeks (0, 2, 6, 14, and 22)	14	7 (50)	9 (64.3)	None	None	NR
	The same regimen plus an additional VDZ dose at week 10	14	5 (35.7)	6 (42.9)

Values are presented as number or number (%).

^aVDZ 300 mg IV at weeks 0, 2, 6 (induction) and then every 8 weeks thereafter (maintenance).

VDZ, vedolizumab; IV, intravenous; NR, not reported.